Consecutive Revenue and EBITDA Growth
Bausch Health, excluding Bausch + Lomb, achieved its 10th consecutive quarter of year-over-year revenue and adjusted EBITDA growth, with a 7% increase in both metrics on a reported basis.
Debt Reduction
The company reduced its debt by approximately $600 million using cash on hand, showcasing strong financial management.
Solta and Salix Double-Digit Growth
Solta saw a 25% growth on a reported basis and 24% on an organic basis, while Salix delivered 12% growth on a reported basis and 11% on an organic basis.
Product-Level Achievements
Triple-digit growth for Cabtreo and Ryaltris, and double-digit growth for Xifaxan and Thermage were observed, indicating strong product performance.